Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Phase 1 Completed 50 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer. Sorafenib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of cancer cells by blocking blood flow to the cancer

Timeline

Start: 2005-12
Primary completion: 2010-05
Completion: —

Publications

Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Oct;31(5):1201-6. doi: 10.1007/s10637-013-0004-2. Epub 2013 Jul 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1 mg/m2	Intravenous
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Subject	Sorafenib	Small molecule	200 mg	Oral
Background	17-N-allylamino-17-demethoxygeldanamycin	Unknown	—	—

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Summary

Timeline

Publications

Drugs

Indications